FI961809L - Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydro-2H-1-bentsopyraanit - Google Patents

Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydro-2H-1-bentsopyraanit Download PDF

Info

Publication number
FI961809L
FI961809L FI961809A FI961809A FI961809L FI 961809 L FI961809 L FI 961809L FI 961809 A FI961809 A FI 961809A FI 961809 A FI961809 A FI 961809A FI 961809 L FI961809 L FI 961809L
Authority
FI
Finland
Prior art keywords
benzopyrans
disubstituted
carbamoyl
dihydro
fluoro
Prior art date
Application number
FI961809A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI961809A7 (fi
FI961809A0 (fi
Inventor
John Leslie Evenden
Eva Maria Hammarberg
Hans Sverker Hansson
Sven Erik Hellberg
Lars George Johansson
Johan Rune Michael Lundkvist
Svante Bertil Ross
Daniel Dungan Sohn
Seth Olov Thorberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of FI961809A0 publication Critical patent/FI961809A0/fi
Publication of FI961809A7 publication Critical patent/FI961809A7/fi
Publication of FI961809L publication Critical patent/FI961809L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
FI961809A 1993-10-28 1994-10-26 Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydro-2H-1-bentsopyraanit FI961809L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/144,671 US5420151A (en) 1989-12-22 1993-10-28 Chroman derivatives
PCT/SE1994/001010 WO1995011891A1 (en) 1993-10-28 1994-10-26 Novel (r)-5-carbamoyl-8-fluoro-3-n,n-disubstituted-amino-3,4-dihydro-2h-1-benzopyranes

Publications (3)

Publication Number Publication Date
FI961809A0 FI961809A0 (fi) 1996-04-26
FI961809A7 FI961809A7 (fi) 1996-05-20
FI961809L true FI961809L (fi) 1996-05-20

Family

ID=22509617

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961809A FI961809L (fi) 1993-10-28 1994-10-26 Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydro-2H-1-bentsopyraanit

Country Status (35)

Country Link
US (9) US5420151A (enExample)
EP (1) EP0725779B1 (enExample)
JP (1) JP3089276B2 (enExample)
CN (1) CN1062269C (enExample)
AT (1) ATE203019T1 (enExample)
AU (1) AU687115B2 (enExample)
BR (1) BR9407910A (enExample)
CA (1) CA2173257C (enExample)
CZ (1) CZ284371B6 (enExample)
DE (1) DE69427704T2 (enExample)
DK (1) DK0725779T3 (enExample)
EE (1) EE03253B1 (enExample)
ES (1) ES2160640T3 (enExample)
FI (1) FI961809L (enExample)
GR (1) GR3036816T3 (enExample)
HR (1) HRP940890B1 (enExample)
HU (1) HUT75060A (enExample)
IL (1) IL111365A (enExample)
IS (1) IS1904B (enExample)
LV (1) LV12811B (enExample)
MY (1) MY111616A (enExample)
NO (1) NO314146B1 (enExample)
NZ (1) NZ275176A (enExample)
PL (1) PL178840B1 (enExample)
PT (1) PT725779E (enExample)
RU (1) RU2142951C1 (enExample)
SA (1) SA94150317B1 (enExample)
SG (1) SG52320A1 (enExample)
SI (1) SI0725779T1 (enExample)
SK (1) SK280527B6 (enExample)
TW (1) TW399049B (enExample)
UA (1) UA44717C2 (enExample)
WO (1) WO1995011891A1 (enExample)
YU (1) YU49048B (enExample)
ZA (1) ZA948353B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616610A (en) * 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
IL114760A (en) * 1991-02-08 1997-11-20 Lilly Co Eli Ring-substituted-2-amino-1,2,3,4-tetrahydronaphthalenes and 3-aminochromanes intermediates thereto
CA2153498A1 (en) * 1993-11-10 1995-05-18 Hidetsura Cho Chroman derivative and medicinal use thereof
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
SE9701438D0 (sv) * 1997-04-17 1997-04-17 Astra Ab A new process
SE510305C2 (sv) * 1997-05-30 1999-05-10 Astra Ab Nytt salt
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
SE9703378D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703377D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
US6204274B1 (en) 1998-04-29 2001-03-20 American Home Products Corporation Indolyl derivatives as serotonergic agents
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6066637A (en) * 1998-06-19 2000-05-23 American Home Products Corporation Indolyl derivatives as serotonergic agents
NZ535574A (en) 2001-01-16 2006-07-28 Astrazeneca Ab Therapeutic heterocyclic compounds
US7032572B2 (en) * 2002-06-04 2006-04-25 Ford Global Technologies, Llc Method for controlling an engine to obtain rapid catalyst heating
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
KR20070088798A (ko) * 2004-12-21 2007-08-29 에프. 호프만-라 로슈 아게 크로만 유도체 및 그의 5-ｈｔ 수용체 리간드로서의 용도
US20060205807A1 (en) * 2005-02-16 2006-09-14 Wyeth Amino-chroman compounds and methods for preparing same
US8846742B2 (en) * 2006-02-14 2014-09-30 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway modulators
BRPI0718351A2 (pt) * 2006-12-12 2019-09-24 Bial Portela & Ca Sa "processo para a preparação do enantiômero s ou r, processo para formar um composto r ou s, uso de um catalisador quiral, composto, sal tartrato do enantiômero s ou r de um composto, complexo de metal de transição e catalisador"
US8473062B2 (en) * 2008-05-01 2013-06-25 Autonomic Technologies, Inc. Method and device for the treatment of headache
US8412336B2 (en) 2008-12-29 2013-04-02 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US8494641B2 (en) 2009-04-22 2013-07-23 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US9320908B2 (en) * 2009-01-15 2016-04-26 Autonomic Technologies, Inc. Approval per use implanted neurostimulator
US20100185249A1 (en) * 2009-01-22 2010-07-22 Wingeier Brett M Method and Devices for Adrenal Stimulation
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
CA2972203C (en) 2017-06-29 2018-07-17 Exxonmobil Upstream Research Company Chasing solvent for enhanced recovery processes
CA2974712C (en) 2017-07-27 2018-09-25 Imperial Oil Resources Limited Enhanced methods for recovering viscous hydrocarbons from a subterranean formation as a follow-up to thermal recovery processes
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
CA2978157C (en) 2017-08-31 2018-10-16 Exxonmobil Upstream Research Company Thermal recovery methods for recovering viscous hydrocarbons from a subterranean formation
CA2983541C (en) 2017-10-24 2019-01-22 Exxonmobil Upstream Research Company Systems and methods for dynamic liquid level monitoring and control
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
US12007369B2 (en) * 2021-04-01 2024-06-11 Saudi Arabian Oil Company Residual corrosion inhibitor monitoring

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795874A (fr) * 1972-02-25 1973-08-23 Glaxo Lab Ltd Procede de preparation d'esters optiquement actifs d'alpha-amino-acides
JPS60152425A (ja) * 1984-01-20 1985-08-10 Oyo Seikagaku Kenkyusho:Kk ラセミ体の新規な光学分割法
US4683223A (en) * 1985-09-09 1987-07-28 Warner-Lambert Company N6 -Benzopyrano-and benzothiopyrano adenosines and methods of use
PH22522A (en) * 1985-09-03 1988-10-17 Ciba Geigy Ag 3-amino-dihydro-1-benzopyrans and benzothiopyrans, their pharmaceutical compositions and method of using said compounds
FR2593504B1 (fr) * 1986-01-30 1988-12-09 Ile De France Nouveaux derives de dihydrobenzofuranne - et de chromane - carboxamides, leurs procedes de preparation et leur utilisation comme neuroleptiques
US4801605A (en) * 1986-08-29 1989-01-31 Ciba-Geigy Corporation 3-amino-dihydro-[1]-benzopyrans and benzothiopyrans
SE8605504D0 (sv) * 1986-12-19 1986-12-19 Astra Laekemedel Ab Novel chroman derivatives
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
US4971982A (en) * 1987-07-06 1990-11-20 Hoffmann-La Roche Inc. Benzopyran derivatives
US5214156A (en) * 1988-03-25 1993-05-25 The Upjohn Company Therapeutically useful tetralin derivatives
US5021432A (en) * 1988-04-26 1991-06-04 Yoshitomi Pharmaceutical Industries, Ltd. Benzopyran compound and its pharmaceutical use
US5026707A (en) * 1988-05-23 1991-06-25 Eli Lilly And Company Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
CA1335591C (en) * 1988-05-23 1995-05-16 James Arthur Nixon Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
FR2639349B1 (fr) * 1988-11-23 1991-02-22 Sanofi Sa Nouveaux derives du chromane actifs sur le systeme nerveux central, leur procede de preparation et les compositions pharmaceutiques en contenant
US5225596A (en) * 1989-01-09 1993-07-06 The Upjohn Company Halo substituted aminotetralins
IL93464A (en) * 1989-02-27 1996-10-16 Lilly Co Eli 2-Amino-1,2,3,4-Tetrahydronaplanin and 3 aminochromes with a transformed ring, a process for their preparation and pharmaceutical preparations containing them
US5306830A (en) * 1989-04-27 1994-04-26 The Upjohn Company Substituted 3-amino chromans
JP2785879B2 (ja) * 1989-05-31 1998-08-13 ジ・アップジョン・カンパニー 治療学的に有用な２―アミノテトラリン誘導体
DE3942418A1 (de) * 1989-12-21 1991-06-27 Guenther Strecker Gestellstab
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
EP0471515B1 (en) * 1990-08-15 1997-03-05 Eli Lilly And Company Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes, 3-aminochromanes and 3-aminothiochromanes
HRP920935A2 (en) * 1991-10-08 1995-08-31 Astra Ab New therapeutically active compound

Also Published As

Publication number Publication date
EP0725779B1 (en) 2001-07-11
US5646309A (en) 1997-07-08
IL111365A (en) 2000-12-06
CN1062269C (zh) 2001-02-21
EP0725779A1 (en) 1996-08-14
PT725779E (pt) 2001-12-28
WO1995011891A1 (en) 1995-05-04
YU62294A (sh) 1997-07-31
RU2142951C1 (ru) 1999-12-20
US5639772A (en) 1997-06-17
GR3036816T3 (en) 2002-01-31
JPH09504287A (ja) 1997-04-28
SG52320A1 (en) 1998-09-28
US5420151A (en) 1995-05-30
PL178840B1 (pl) 2000-06-30
FI961809A7 (fi) 1996-05-20
DE69427704D1 (de) 2001-08-16
CN1136811A (zh) 1996-11-27
NO961687D0 (no) 1996-04-26
UA44717C2 (uk) 2002-03-15
IL111365A0 (en) 1994-12-29
PL314086A1 (en) 1996-08-19
CA2173257C (en) 2005-12-06
US5641807A (en) 1997-06-24
FI961809A0 (fi) 1996-04-26
NO314146B1 (no) 2003-02-03
AU8069794A (en) 1995-05-22
SI0725779T1 (enExample) 2001-12-31
IS4226A (is) 1995-04-29
CZ111496A3 (en) 1996-09-11
US5650524A (en) 1997-07-22
HRP940890A2 (en) 1996-12-31
DK0725779T3 (da) 2001-10-29
NZ275176A (en) 1997-11-24
SK43696A3 (en) 1996-10-02
HUT75060A (en) 1997-03-28
ES2160640T3 (es) 2001-11-16
HRP940890B1 (en) 2001-12-31
CZ284371B6 (cs) 1998-11-11
US5656657A (en) 1997-08-12
IS1904B (is) 2003-11-20
AU687115B2 (en) 1998-02-19
LV12811B (lv) 2002-08-20
ZA948353B (en) 1995-05-02
HU9601103D0 (en) 1996-06-28
DE69427704T2 (de) 2002-05-02
HK1002898A1 (en) 1998-09-25
YU49048B (sh) 2003-07-07
US5500425A (en) 1996-03-19
TW399049B (en) 2000-07-21
EE03253B1 (et) 2000-02-15
SA94150317B1 (ar) 2005-10-15
US5639784A (en) 1997-06-17
NO961687L (no) 1996-06-03
LV12811A (en) 2002-04-20
US5656658A (en) 1997-08-12
CA2173257A1 (en) 1995-05-04
JP3089276B2 (ja) 2000-09-18
SK280527B6 (sk) 2000-03-13
BR9407910A (pt) 1996-11-26
ATE203019T1 (de) 2001-07-15
MY111616A (en) 2000-09-27

Similar Documents

Publication Publication Date Title
FI953489A0 (fi) 2,6-diaminopuriinijohdannaisia
FI954651A7 (fi) Mahdollisesti substituoidut 6,8-kinoliinit
FI961809A7 (fi) Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydr o-2H-1-bentsopyraanit
FI943084A7 (fi) Uusia sulfonyyliaminopyrimidiinejä
NO943999L (no) 1-aminoetylindolderivater
FI923314L (fi) Substituerade cyklopropylamino-1,3,5-triaziner
EP0657163A4 (en) ANTITUSSIVA.
DE69618634D1 (de) 1,4-benzodioxin-derivate
DE59507222D1 (de) Substituierte 1,2,3,4-tetrahydro-5-nitro-pyrimidine
FI933151L (fi) 5,10 metylentetrahydrofolsyre-cyklodextrin-inneslutningsfoereningar
BR9609884A (pt) N-aril- 1,2,4-triazolin-5-onas
NO932842L (no) 1,4-benzodioksanderivater
FI933980A0 (fi) Skyddsplagg foer hygienkraevande objekt, saosom operationssalar
FI931459L (fi) Sammansaettningar med 1-klor-2,2,2-trifluoretyldifluor-metyleter
DE59308564D1 (de) 2,4-Dialkyl-6-sec-alkylphenole
EP0811014A4 (en) NEW BACTERIOCINE, PISCICOLIN 126
TR27962A (tr) Ikame edilmis 2-aril-oksazinler ve -tiyazinler.
FI941909A0 (fi) 2,6-disubstituoidut 4-kinolyylidihydropyridiinit
BR9508248A (pt) 1,2,4,6-Tiatriazinas herbicidas
NO944024L (no) 1,2-dihydro-2-okso-pyridin
FI933872A7 (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 1,3,4-bensotriazepin-5(4H)-on-derivat
NO943791D0 (no) 1,2-dihydro-2-okso-3-metylsulfonylaminometylpyridin
NO942212D0 (no) 13,14-dihydro-PGF2
ITMI931785A0 (it) Valilamidi di 7x-amino-1, 1-dioxo-cefem
NO922732D0 (no) 3,4-dehydropiperidinderivater

Legal Events

Date Code Title Description
MA Patent expired